Effect of dual bronchodilators plus preoperative rehabilitation in operable LC & chronic obstructive pulmonary disease.

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2024-12-01 Epub Date: 2024-11-28 DOI:10.1080/14796694.2024.2430164

Rong Zhou, Yan Qin, Song Hu, Yangyang Xu, Chunlai Feng

{"title":"Effect of dual bronchodilators plus preoperative rehabilitation in operable LC & chronic obstructive pulmonary disease.","authors":"Rong Zhou, Yan Qin, Song Hu, Yangyang Xu, Chunlai Feng","doi":"10.1080/14796694.2024.2430164","DOIUrl":null,"url":null,"abstract":"Background: This study analyzed the application of dual bronchodilators in patients with non-small cell lung cancer (NSCLC) & chronic obstructive pulmonary disease (COPD) during the perioperative period.Research design and methods: A total of 100 patients with moderate to severe COPD who underwent thoracoscopic lobectomy were divided into two groups. The patients in the observation group (group O) were treated with umeclidinium/vilanterol and conventional treatment (oxygen therapy, assisted expectoration, respiratory rehabilitation training) during the perioperative period. The patients in the control group (group C) received conventional treatment. Lung function, arterial blood gas values, quality of life, postoperative adverse reactions, days of postoperative chest tube placement and hospitalization were assessed.Results: Before surgery, group O presented higher FEV1, FVC, PEF and MVV, elevated PO2 and reduced PCO2, lower CAT scores compared with the group C (p < 0.05). The group O demonstrated fewer perioperative adverse reactions, and shorter days of postoperative chest tube and hospitalization compared with the group C (p < 0.05).Conclusions: Perioperative inhalation of umeclidinium/vilanterol can effectively protect arterial blood gas and respiratory function in patients with LC complicated with COPD.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3471-3476"},"PeriodicalIF":3.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776851/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2430164","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This study analyzed the application of dual bronchodilators in patients with non-small cell lung cancer (NSCLC) & chronic obstructive pulmonary disease (COPD) during the perioperative period.

Research design and methods: A total of 100 patients with moderate to severe COPD who underwent thoracoscopic lobectomy were divided into two groups. The patients in the observation group (group O) were treated with umeclidinium/vilanterol and conventional treatment (oxygen therapy, assisted expectoration, respiratory rehabilitation training) during the perioperative period. The patients in the control group (group C) received conventional treatment. Lung function, arterial blood gas values, quality of life, postoperative adverse reactions, days of postoperative chest tube placement and hospitalization were assessed.

Results: Before surgery, group O presented higher FEV1, FVC, PEF and MVV, elevated PO₂ and reduced PCO₂, lower CAT scores compared with the group C (p < 0.05). The group O demonstrated fewer perioperative adverse reactions, and shorter days of postoperative chest tube and hospitalization compared with the group C (p < 0.05).

Conclusions: Perioperative inhalation of umeclidinium/vilanterol can effectively protect arterial blood gas and respiratory function in patients with LC complicated with COPD.

查看原文本刊更多论文

双支气管扩张剂加术前康复治疗对可手术的 LC 和慢性阻塞性肺病的效果。

背景：本研究分析了双支气管扩张剂在非小细胞肺癌（NSCLC）和慢性阻塞性肺疾病（COPD）患者围手术期的应用情况：将100名接受胸腔镜肺叶切除术的中重度COPD患者分为两组。观察组（O 组）患者在围手术期接受优甲乐/维兰特罗治疗和常规治疗（氧疗、辅助排痰、呼吸康复训练）。对照组（C 组）患者接受常规治疗。对肺功能、动脉血气值、生活质量、术后不良反应、术后胸管置入天数和住院天数进行了评估：结果：与 C 组相比，O 组患者术前的 FEV1、FVC、PEF 和 MVV 均较高，PO2 升高，PCO2 降低，CAT 评分较低（P P 结论：O 组患者术前的 FEV1、FVC、PEF 和 MVV 均较高，PO2 升高，PCO2 降低，CAT 评分较低）：围术期吸入优甲乐胺/维兰特罗能有效保护并发慢性阻塞性肺疾病的 LC 患者的动脉血气和呼吸功能。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.